Increased Serum C-Reactive Protein Levels Imply Chronic Inflammation in Men with Benign Prostatic Hyperplasia and Predominant Storage Lower Urinary Tract Symptoms

April 2013 in “ The Journal of Urology ”

Shun-Fa Hung, Shiu‐Dong Chung, Hann‐Chorng Kuo

benign prostatic hyperplasia C-reactive protein lower urinary tract symptoms prostate specific antigen tolterodine Doxazosin chronic inflammation bladder disorders BPH CRP LUTS PSA

TLDR Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

The study from April 2013 involved 612 men with benign prostatic hyperplasia (BPH) and examined the link between serum C-reactive protein (CRP) levels and lower urinary tract symptoms (LUTS), particularly storage symptoms. The findings indicated a significant correlation between higher CRP levels and storage symptoms, as well as with age and prostate specific antigen (PSA), but not with total or voiding symptoms. Treatment with tolterodine in patients with a voiding/storage ratio less than 1 led to a significant reduction in CRP levels and symptom improvement, whereas treatment with Doxazosin in those with a ratio greater than 1 did not yield significant changes. The study concluded that increased serum CRP levels suggest chronic inflammation is more related to storage LUTS and bladder disorders than to voiding LUTS and outlet obstruction.

View this study on auajournals.org →

Discuss this study in the Community →

Related Community Posts Join

6 / 84 results

community New and Interesting HairLoss Studies/Papers/Reviews

in Treatment 41 upvotes 5 years ago

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

community FCE 28260: A Forgotten 5α-Reductase Inhibitor

in Research 330 upvotes 5 months ago

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

community Watching my younger brother bald hurts so much.

in Treatment 269 upvotes 5 months ago

A 19-year-old is distressed about his 17-year-old autistic brother's hair loss, projecting his own insecurities despite being on finasteride and dutasteride. Replies suggest the brother might not care about balding, and the poster should address his own issues.

community Taking Charge of Your Hair: The "Big 3 Stack" Explained for 2023

in Research/Science 129 upvotes 1 year ago

The "Big 3 Stack" for hair loss treatment, which includes Minoxidil for hair density improvement, Ketoconazole shampoo for enhancing hair volume and thickness, and Finasteride for blocking hair loss causing hormones. Microneedling can boost Minoxidil's effects.

community A meta analysis of 18 popular hair loss treatments. An 2022 guide on efficacy. From finasteride and minoxidil to caffeine shampoo, saw palmetto and biotin. 96 Scientific References included.

in Research/Science 104 upvotes 2 years ago

Most hair loss treatments are ineffective; only finasteride, dutasteride, and minoxidil show effectiveness.

community COMPLETE OVERVIEW of the Treatment of androgenetic alopecia in men

26 upvotes 10 years ago

Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.

Similar Research

5 / 1000+ results

research Androgenetic Alopecia as an Early Marker of Benign Prostatic Hyperplasia

28 citations, August 2011 in “Journal of The American Academy of Dermatology”

Early hair loss may indicate prostate issues.

research Benign Prostatic Hyperplasia, Metabolic Syndrome, and Androgenic Alopecia: Is There a Possible Relationship?

7 citations, February 2016 in “Arab journal of urology”

People with early hair loss may have a higher chance of enlarged prostate and metabolic syndrome, so they should be checked for urinary and metabolic issues.

research Associations Between Variants in the Cyclooxygenase 2 Enzyme Gene (PTGS2) and Development of Benign Prostate Enlargement

November 2012 in “The Journal of Urology”

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population

research Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population

16 citations, May 2013 in “Urology”

Metabolic syndrome linked to urinary symptoms; hair loss not significant.

Finasteride, Not Tamsulosin, Increases Severity of Erectile Dysfunction and Decreases Testosterone Levels in Men With Benign Prostatic Hyperplasia

research Finasteride, Not Tamsulosin, Increases Severity of Erectile Dysfunction and Decreases Testosterone Levels in Men With Benign Prostatic Hyperplasia

20 citations, June 2015 in “Hormone Molecular Biology and Clinical Investigation”

Finasteride worsens erectile dysfunction and lowers testosterone in men with enlarged prostates, unlike tamsulosin.